News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celsus Therapeutics' MRX-6 Selected as One of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence



10/21/2013 9:18:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK and LONDON, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced that the Company's MRX-6 treatment for eczema has been selected as one of the "Top 10 Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Windhover Information, of Elsevier Business Intelligence, a global leader in the field of healthcare industry information. Celsus management will present the project to a select group of pharmaceutical company executives at Windhover's Therapeutic Area Partnerships meeting in Boston, November 18-20.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES